Anzeige
Mehr »
Montag, 02.03.2026 - Börsentäglich über 12.000 News
Erste Psilocybin-Behandlungen laufen - warum steht Optimi noch bei Pennystock-Level?!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PKM6 | ISIN: US79957L1008 | Ticker-Symbol:
NASDAQ
27.02.26 | 18:45
20,600 US-Dollar
-2,74 % -0,580
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
SANARA MEDTECH INC Chart 1 Jahr
5-Tage-Chart
SANARA MEDTECH INC 5-Tage-Chart

Aktuelle News zur SANARA MEDTECH Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
23.01.Sanara MedTech expects Q4 revenue between $27.2M and $27.7M1
23.01.Sanara MedTech expects 19% revenue growth for 2025, issues 2026 guidance2
23.01.Sanara MedTech Inc. - 8-K, Current Report2
23.01.Sanara MedTech Inc. Reports Unaudited Preliminary Financial Results for the Fourth Quarter and Full Year 2025; Introduces Full Year 2026 Financial Guidance149FORT WORTH, TX, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. ("Sanara MedTech," "Sanara," the "Company," "we," "our" or "us") (Nasdaq: SMTI), a medical technology company focused on developing...
► Artikel lesen
07.01.Vizient-Vertrag beflügelt Aktie von Sanara MedTech1
07.01.Sanara MedTech's BIASURGE receives Vizient innovative technology contract1
10.12.25Sanara MedTech Inc. and Biomimetic Innovations Provide Update on OsStic180Poised for U.S. market launch in Q1 2027 following the achievement of recent milestones and OsStic's granted patent in 2025 FORT WORTH, TX, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. ("Sanara...
► Artikel lesen
26.11.25Sanara MedTech Inc. - 8-K, Current Report-
SANARA MEDTECH Aktie jetzt für 0€ handeln
12.11.25Sanara MedTech Inc. - 10-Q, Quarterly Report8
12.11.25Sanara MedTech signals strategic shift with THP discontinuation and continued surgical growth focus3
12.11.25Sanara MedTech GAAP EPS of $0.09 beats by $0.30, revenue of $26.3M misses by $0.33M4
12.11.25Sanara MedTech Inc. - 8-K, Current Report1
11.11.25Sanara MedTech discontinues Tissue Health Plus segment2
11.11.25Sanara MedTech Inc. Announces Strategic Realignment to Focus on Surgical Business172Completes Evaluation of Strategic Alternatives for Tissue Health Plus Segment FORT WORTH, TX, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. ("Sanara," the "Company," "we," "our" or "us")...
► Artikel lesen
03.09.25Sanara MedTech stock falls after CEO succession announcement1
02.09.25Sanara MedTech Inc. Announces Chief Executive Officer Transition206Seth Yon Appointed President, Chief Executive Officer and Director; Ron Nixon to Remain Executive Chairman FORT WORTH, TX, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. ("Sanara," the "Company...
► Artikel lesen
14.05.25Sanara MedTech Inc. Reports First Quarter 2025 Financial Results (Unaudited)207Q1 Net Revenue Increased 26% Year-Over-Year FORT WORTH, TX, May 14, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. ("Sanara," the "Company," "we," "our" or "us") (Nasdaq: SMTI), a medical technology...
► Artikel lesen
25.03.25Sanara MedTech Inc. Reports Fourth Quarter and Full Year 2024 Financial Results (Unaudited)313Q4 Net Revenue Increased 49% Year-Over-Year; 2024 Net Revenue Increased 33% Year-Over-Year FORT WORTH, TX, March 25, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. ("Sanara," the "Company," "we," "our"...
► Artikel lesen
18 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1